scholarly journals Endogenous insulin secretion and suppression during and after sepsis in critically ill patients: implications for tight glycemic control protocols

Critical Care ◽  
2011 ◽  
Vol 15 (S1) ◽  
Author(s):  
CG Pretty ◽  
PD Docherty ◽  
J Lin ◽  
L Pfeifer ◽  
U Jamaludin ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Glycemic Control ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Tight Glycemic Control ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Control Protocols

scholarly journals Estimation of Plasma Insulin and Endogenous Insulin Secretion in Critically Ill Patients Using Intensive Control Insulin-Nutrition-Glucose Model

2017 ◽  
Vol 23 (6) ◽  
pp. 5511-5514
Author(s):  
Ummu K Jamaludin ◽  
Fatanah M Suhaimi ◽  
Normy Norfiza A Razak ◽  
Azrina M Ralib ◽  
Mohd Basri Mat Nor
Keyword(s):  
Insulin Secretion ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Plasma Insulin ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Intensive Control

scholarly journals Endogenous insulin secretion in critically ill patients

Critical Care ◽  
2012 ◽  
Vol 16 (S1) ◽  
Author(s):  
C Pretty ◽  
A Le Compte ◽  
J Lin ◽  
G Shaw ◽  
JG Chase
Keyword(s):  
Insulin Secretion ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin

scholarly journals Second pilot trials of the STAR-Liege protocol for tight glycemic control in critically ill patients

2012 ◽  
Vol 11 (1) ◽  
pp. 58 ◽  
Author(s):  
Sophie Penning ◽  
Aaron J Le Compte ◽  
Paul Massion ◽  
Katherine T Moorhead ◽  
Christopher G Pretty ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Tight Glycemic Control ◽  
Pilot Trials

Tight Glycemic Control in Critically Ill Patients

JAMA ◽  
2010 ◽  
Vol 303 (17) ◽  
pp. 1694
Author(s):  
Mario R. Castellanos
Keyword(s):  
Glycemic Control ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Tight Glycemic Control

A Pilot Study of the SPRINT Protocol for Tight Glycemic Control in Critically Ill Patients

2006 ◽  
Vol 8 (4) ◽  
pp. 449-462 ◽  
Author(s):  
Timothy Lonergan ◽  
Aaron Le Compte ◽  
Mike Willacy ◽  
J. Geoffrey Chase ◽  
Geoffrey M. Shaw ◽  
...  
Keyword(s):  
Pilot Study ◽  
Glycemic Control ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Tight Glycemic Control

scholarly journals The role of insulin analogues in the current treatment of diabetes mellitus

2006 ◽  
Vol 59 (11-12) ◽  
pp. 539-544 ◽  
Author(s):  
Milena Mitrovic ◽  
Pavle Pantelinac ◽  
Jovanka Radosavljevic ◽  
Ivana Bajkin ◽  
Ljiljana Todorovic-Djilas
Keyword(s):  
Insulin Secretion ◽  
Glycemic Control ◽  
Human Insulin ◽  
Basal Insulin ◽  
Current Treatment ◽  
Insulin Analogues ◽  
Endogenous Insulin Secretion ◽  
Neutral Ph ◽  
Endogenous Insulin ◽  
Rapid Action

Introduction. Ever since insulin was discovered by Banting and Best in 1921, all further researches in this field had been conducted with one goal: to find new insulin molecules which would provide better glycemic control with fewer side effects i.e. to mimic endogenous physiological insulin secretion. Normal insulin secretion. In healthy individuals, endogenous insulin secretion can be classified as basal (which provides basal glucose homeostasis) and stimulated (as a response to a meal). Conventional insulin preparations - human insulin, have time-action profiles that cannot fully imitate endogenous insulin secretion, thus leading to postprandial hyperglicemia and high glycemic oscilations during the day. Rapid-acting analogues. Rapid acting analogues should have a time-action profile with onset of less than one hour, duration less than four hours, hypoglycemic potency equal or greater than that of human insulin, and similar effects in all patients. Two rapid action analouges, lispro and aspart are available. Basal insulin analogues. The ideal basal insulin should provide slow and constant absorption, long half-life that would provide once daily dosing (or every other day), and peakless effect. Insulin glargine led to solubility at pH 4 and to slow absorption in neutral pH environment. Insulin detemir is a soluble insulin analogue with neutral pH and affinity to bind to serum albumin, thus gaining prolonged action. Mitogenic influence. The mitogenic influence of insulin is due to the affinity to bind to IGF-1 receptors. Following two-year administration of glargine in mice and rats, systemic carcinogenic potential was not found, though there were reports of hepatocellular carcinomas, which are frequently found in these animals. Conclusion. In the last two decades, many trials have shown that unsatisfactory glycemic control leads to chronic complications in both types of diabetes. Using basal glucose level, postprandial glycemy and HbA1c as matabolic parameters, it has been proven that only strict glycemic control can lower the risk of developing complications. Discovery of insulin analogues (both rapid acting and basal) enables physicians to provide better glycoregulation and less hypoglycemic incidents to their patients. .

scholarly journals First pilot trial of the STAR-Liege protocol for tight glycemic control in critically ill patients

2012 ◽  
Vol 108 (2) ◽  
pp. 844-859 ◽  
Author(s):  
Sophie Penning ◽  
Aaron J. Le Compte ◽  
Katherine T. Moorhead ◽  
Thomas Desaive ◽  
Paul Massion ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Pilot Trial ◽  
Tight Glycemic Control
Sign in / Sign up

Export Citation Format

Share Document